Restricted and repetitive behaviors

限制和重复行为
  • 文章类型: Journal Article
    目前还没有批准的药物治疗自闭症谱系障碍(ASD)的核心症状。该网络荟萃分析调查了ASD的药理和饮食补充治疗。
    我们在ClinicalTrials.gov中搜索了最短持续时间为7天的随机对照试验(RCT),EMBASE,MEDLINE,PsycINFO,世卫组织-ICTRP(自成立至2018年7月8日),CENTRAL和PubMed(截至2021年11月3日)。共同主要结果是核心症状(社交沟通困难-SCD,重复行为-RB,总体核心症状-OCS)通过经过验证的量表和标准化平均差异(SMD)进行测量。相关症状,例如,易怒/攻击性和注意力缺陷/多动障碍(ADHD)症状,辍学和重要的副作用,作为次要结局进行调查。在随机效应配对和网络荟萃分析中,分别对儿童/青少年和成人的研究进行了分析。
    我们分析了41种药物和17种膳食补充剂的数据,来自儿童/青少年的125项RCT(n=7450名参与者)和成人的18项RCT(n=1104)。与安慰剂相比,以下药物可以改善至少一个核心症状领域:阿立哌唑(k=6项分析研究,SCD:SMD=0.2795%CI[0.09,0.44],RB:0.48[0.26,0.70]),托莫西汀(k=3,RB:0.49[0.18,0.80]),布美他尼(k=4,RB:0.35[0.09,0.62],OCS:0.61[0.31,0.91]),和利培酮(k=4,SCM:0.31[0.06,0.55],RB:0.60[0.29,0.90];k=3,OCS:1.18[0.75,1.61])儿童/青少年;氟西汀(k=1,RB:1.20[0.45,1.96]),氟伏沙明(k=1,RB:1.04[0.27,1.81]),成人催产素(k=6,RB:0.41[0.16,0.66])和利培酮(k=1,RB:0.97[0.21,1.74])。有一些肌肽改善的迹象,氟哌啶醇,亚叶酸,胍法辛,omega-3-脂肪酸,益生菌,萝卜硫素,tidegusib和丙戊酸盐,但不精确也不健壮。对这些估计的信心非常低或很低,除了适度的催产素。药物在改善相关症状方面有很大不同,以及他们的副作用。
    大多数研究动力不足(20-80名参与者的样本量),持续时间短(8-13周),大约三分之一的人集中在相关症状上。网络主要是星形的,并且有报告偏倚的迹象。没有测量核心症状变化的最佳评定量表。
    一些药物可以改善核心症状,尽管这可能是次要的相关症状的改善。关于其有效性和安全性的证据是初步的;因此,不推荐针对核心症状的常规药物处方。试用注册PROSPERO-IDCRD42019125317。
    There is still no approved medication for the core symptoms of autism spectrum disorder (ASD). This network meta-analysis investigated pharmacological and dietary-supplement treatments for ASD.
    We searched for randomized-controlled-trials (RCTs) with a minimum duration of seven days in ClinicalTrials.gov, EMBASE, MEDLINE, PsycINFO, WHO-ICTRP (from inception up to July 8, 2018), CENTRAL and PubMed (up to November 3, 2021). The co-primary outcomes were core symptoms (social-communication difficulties-SCD, repetitive behaviors-RB, overall core symptoms-OCS) measured by validated scales and standardized-mean-differences (SMDs). Associated symptoms, e.g., irritability/aggression and attention-deficit/hyperactivity disorder (ADHD) symptoms, dropouts and important side-effects, were investigated as secondary outcomes. Studies in children/adolescents and adults were analyzed separately in random-effects pairwise and network meta-analyses.
    We analyzed data for 41 drugs and 17 dietary-supplements, from 125 RCTs (n = 7450 participants) in children/adolescents and 18 RCTs (n = 1104) in adults. The following medications could improve at least one core symptom domain in comparison with placebo: aripiprazole (k = 6 studies in analysis, SCD: SMD = 0.27 95% CI [0.09, 0.44], RB: 0.48 [0.26, 0.70]), atomoxetine (k = 3, RB:0.49 [0.18, 0.80]), bumetanide (k = 4, RB: 0.35 [0.09, 0.62], OCS: 0.61 [0.31, 0.91]), and risperidone (k = 4, SCM: 0.31 [0.06, 0.55], RB: 0.60 [0.29, 0.90]; k = 3, OCS: 1.18 [0.75, 1.61]) in children/adolescents; fluoxetine (k = 1, RB: 1.20 [0.45, 1.96]), fluvoxamine (k = 1, RB: 1.04 [0.27, 1.81]), oxytocin (k = 6, RB:0.41 [0.16, 0.66]) and risperidone (k = 1, RB: 0.97 [0.21,1.74]) in adults. There were some indications of improvement by carnosine, haloperidol, folinic acid, guanfacine, omega-3-fatty-acids, probiotics, sulforaphane, tideglusib and valproate, yet imprecise and not robust. Confidence in these estimates was very low or low, except moderate for oxytocin. Medications differed substantially in improving associated symptoms, and in their side-effect profiles.
    Most of the studies were inadequately powered (sample sizes of 20-80 participants), with short duration (8-13 weeks), and about a third focused on associated symptoms. Networks were mainly star-shaped, and there were indications of reporting bias. There was no optimal rating scale measuring change in core symptoms.
    Some medications could improve core symptoms, although this could be likely secondary to the improvement of associated symptoms. Evidence on their efficacy and safety is preliminary; therefore, routine prescription of medications for the core symptoms cannot be recommended. Trial registration PROSPERO-ID CRD42019125317.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    社交和运动技能缺陷是自闭症谱系障碍(ASD)患者的普遍特征。这项系统的研究综述调查了ASD患者之间广泛的社交技能和运动技能是否以及如何相关。我们用PubMed搜索了用英语写的文章,使用这些研究纳入标准:(a)以前被诊断为自闭症的个体中社交和运动和技能之间的关联;(b)使用了一种或多种社交技能指标;(c)使用了一种或多种总体或精细运动技能指标.我们把数据分为两类,我们将这些变量的关联基于相关系数,p值,决定系数,和作者\'对\"的描述可能关联\"和\"可能不关联。“尽管这些相关研究存在异质性,社交技能和运动技能之间很可能存在关联。在总共16项研究中,12报告了这些技能之间的关联。三项研究报告说,精细运动技能与社交技能的关系比粗大运动技能更强。在与社交技能相关的总体运动技能中,对象控制技能似乎与社交技能联系最紧密。在精细的运动技能中,手工灵巧似乎与社交技能最密切相关。
    Social communication and motor skill deficits are prevalent characteristics of individuals with autism spectrum disorder (ASD). This systematic research review investigates whether and how broad social skills and motor skills may be related among individuals with ASD. We performed a PubMed search of articles written in English, using these study inclusion criteria: (a) an association between social and motor and skills among individuals previously diagnosed with autism; (b) one or more social skills measures were used; and (c) one or more measures of gross or fine motor skills were used. We classified data into two categories, and we based the association of these variables on correlation coefficients, p-values, coefficients of determination, and authors\' description of \"may be associated\" and \"may not be associated.\" Despite heterogeneity among these relevant studies, a highly likely association between social and motor skills emerged. Of a total of 16 studies reviewed, 12 reported associations between these skill sets. Three studies reported that fine motor skills had a stronger relationship with social skills than did gross motor skills. Among the gross motor skills associated with social skills, object control skills seemed most closely linked to social skills. Among fine motor skills, manual dexterity seemed to most closely related to social skills.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

公众号